Biondo Investment Advisors LLC Acquires 85 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Biondo Investment Advisors LLC raised its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 42,757 shares of the company’s stock after purchasing an additional 85 shares during the quarter. IDEXX Laboratories makes up about 2.4% of Biondo Investment Advisors LLC’s investment portfolio, making the stock its 9th largest position. Biondo Investment Advisors LLC owned approximately 0.05% of IDEXX Laboratories worth $17,677,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. FSA Wealth Management LLC bought a new stake in shares of IDEXX Laboratories during the third quarter worth $25,000. Rialto Wealth Management LLC bought a new stake in IDEXX Laboratories during the 4th quarter worth about $30,000. Retirement Wealth Solutions LLC acquired a new position in IDEXX Laboratories during the 4th quarter valued at about $31,000. Kestra Investment Management LLC bought a new position in shares of IDEXX Laboratories in the 4th quarter valued at about $38,000. Finally, Crews Bank & Trust bought a new position in shares of IDEXX Laboratories in the 4th quarter valued at about $41,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analysts Set New Price Targets

IDXX has been the subject of several recent analyst reports. Barclays increased their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a report on Tuesday, February 4th. Leerink Partners started coverage on IDEXX Laboratories in a research note on Monday, December 2nd. They set an “outperform” rating and a $500.00 target price for the company. Morgan Stanley dropped their target price on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a report on Wednesday, January 29th. Bank of America upped their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a report on Tuesday, February 4th. Finally, StockNews.com lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Tuesday. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $533.75.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX opened at $415.87 on Friday. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The business has a 50-day moving average of $437.07 and a 200-day moving average of $443.27. The stock has a market capitalization of $33.71 billion, a price-to-earnings ratio of 38.98, a PEG ratio of 3.41 and a beta of 1.39. IDEXX Laboratories, Inc. has a fifty-two week low of $398.50 and a fifty-two week high of $548.88.

Insider Activity at IDEXX Laboratories

In other news, Director M Anne Szostak sold 3,000 shares of the stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the sale, the director now owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP George Fennell sold 9,986 shares of the company’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the sale, the executive vice president now directly owns 8,176 shares in the company, valued at $3,781,645.28. This trade represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 2.11% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.